The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma

Huazhong University of Science and Technology

Status: Invitation-only

Conditions: Squamous Cell Lung Cancer

Treatments: Other: Efficacy observation

Study type: Observational

Funder types: Other

Identifiers

NCT06647836

XHJY20240908

Details and patient eligibility

About

The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC). The primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-NSCLC patients. Biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.

Full description

The medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with sq-NSCLC;
• Receiving immunotherapy combined with or without chemotherapy as first-line treatment;
• ≥ 18 years and ≤ 80 years old;
• No previous treatment in the lungs or any other organ.

Exclusion criteria

• History of cancer treatment;
• History of other malignant tumors;
• Irregular treatment or poor compliance;
• Incomplete clinical information or lost to follow-up.

Trial design

1,000 participants in 4 patient groups

untreated sq-NSCLC patients

Description:

Patients diagnosed with sq-NSCLC for the first time

Treatment:

Other: Efficacy observation

sq-NSCLC patients treated with immunotherapy for -2-3 cycles

Description:

sq-NSCLC patients treated with immunotherapy combined with or without chemotherapy as first-line treatment for 2-3 cycles.

Treatment:

Other: Efficacy observation

sq-NSCLC patients receiving immunotherapy with poor efficacy

Description:

sq-NSCLC patients treated with immunotherapy combined with or without chemotherapy as first-line treatment and experience disease progression within six months.

Treatment:

Other: Efficacy observation

sq-NSCLC patients receiving immunotherapy with good efficacy

Description:

sq-NSCLC patients treated with immunotherapy combined with or without chemotherapy as first-line treatment and having progression-free survival longer than six months.

Treatment:

Other: Efficacy observation